Search Results

Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, “Ono”) today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.

ONO Pharmaceutical, Co., Ltd., and Deciphera Pharmaceuticals, Inc. announced that on April 29, 2024, ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO.

PRISM BioLab, Co. Ltd. announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Sibylla Biotech announced a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. that will access Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting technology to identify and develop candidates for multiple therapeutic targets in the field of Central Nervous System disorders.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK) today announces a worldwide drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (Ono), to generate novel bifunctional fusion proteins targeting certain pathways in autoimmune and inflammatory diseases.